We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $4.46B
This Fund
S&P 500
This Quarter Est. Return
-11.93%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.06B
AUM Growth
+$226M
Cap. Flow
+$653M
Cap. Flow %
21.38%
Top 10 Hldgs %
83.2%
Holding
374
New
73
Increased
133
Reduced
109
Closed
49

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$334M
2
JD icon
JD.com
JD
+$84.6M
3
BIDU icon
Baidu
BIDU
+$84.3M
4
NTES icon
NetEase
NTES
+$50.9M
5
PDD icon
Pinduoduo
PDD
+$50.6M

Top Sells

Rank Stock Value
1
NIO icon
NIO
NIO
+$10.7M
2
KC
Kingsoft Cloud Holdings
KC
+$9.2M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$7.55M
4
QQQ icon
Invesco QQQ Trust
QQQ
+$7.48M
5
MOMO
Hello Group
MOMO
+$6.64M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 63.45%
2 Communication Services 21.89%
3 Technology 6.77%
4 Healthcare 2.16%
5 Financials 1.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
226
United Therapeutics
UTHR
$22.2B
$278K 0.01%
+1,551
New +$295K
ISEE
227
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$276K 0.01%
16,370
+4,542
+38% +$67.1K
FOLD
228
DELISTED
Amicus Therapeutics
FOLD
$273K 0.01%
28,875
+12,006
+71% +$113K
HRTX icon
229
Heron Therapeutics
HRTX
$62.3M
$273K 0.01%
47,763
+29,396
+160% +$215K
LOW icon
230
Lowe's Companies
LOW
$116B
$273K 0.01%
1,351
-180
-12% -$41.4K
MRTX
231
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$273K 0.01%
+3,321
New +$340K
BMRN icon
232
BioMarin Pharmaceuticals
BMRN
$12.4B
$272K 0.01%
+3,531
New +$295K
BCRX icon
233
BioCryst Pharmaceuticals
BCRX
$2.51B
$271K 0.01%
16,641
+1,756
+12% +$28.2K
NVAX icon
234
Novavax
NVAX
$1.48B
$271K 0.01%
+3,676
New +$328K
LGND icon
235
Ligand Pharmaceuticals
LGND
$5.59B
$270K 0.01%
+3,846
New +$279K
CI icon
236
Cigna
CI
$73.4B
$269K 0.01%
1,121
-184
-14% -$43.1K
SRPT icon
237
Sarepta Therapeutics
SRPT
$2.23B
$269K 0.01%
+3,446
New +$264K
ZM icon
238
Zoom
ZM
$28.9B
$269K 0.01%
2,298
– –
BHVN
239
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$268K 0.01%
2,259
+520
+30% +$64.9K
CLDX icon
240
Celldex Therapeutics
CLDX
$3.13B
$267K 0.01%
+7,838
New +$251K
EW icon
241
Edwards Lifesciences
EW
$52B
$266K 0.01%
2,258
-127
-5% -$14.2K
KYMR icon
242
Kymera Therapeutics
KYMR
$9.9B
$264K 0.01%
6,228
+3,078
+98% +$130K
CYTK icon
243
Cytokinetics
CYTK
$10.1B
$263K 0.01%
7,154
+2,350
+49% +$83.5K
PRTA icon
244
Prothena Corp
PRTA
$480M
$263K 0.01%
+7,202
New +$260K
BDX icon
245
Becton Dickinson
BDX
$51.6B
$262K 0.01%
1,009
-154
-13% -$39.7K
AGIO icon
246
Agios Pharmaceuticals
AGIO
$2.01B
$260K 0.01%
+8,923
New +$273K
IT icon
247
Gartner
IT
$12.5B
$260K 0.01%
875
+67
+8% +$19.4K
ALLO icon
248
Allogene Therapeutics
ALLO
$705M
$258K 0.01%
+28,315
New +$295K
CDW icon
249
CDW
CDW
$18.4B
$258K 0.01%
1,441
+112
+8% +$20.5K
NUGT icon
250
Direxion Daily Gold Miners Index Bull 2X ETF
NUGT
$1.38B
$258K 0.01%
3,646
-20,455
-85% -$1.16M
8 9
10
11 12

Similar funds

ACM
Advent Capital Management New York $4.46B AUM 0.73% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
MAM
Magellan Asset Management Sydney, Australia $4.47B AUM 4.2% 1-Year Est. Return
AP
Americana Partners Houston, Texas $4.44B AUM 29.45% 1-Year Est. Return
BP
BC Partners New York $4.43B AUM 49.12% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
AOI
Auto-Owners Insurance Lansing, Michigan $4.43B AUM 30.05% 1-Year Est. Return
WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return

E Fund Management's Q1 2022 Portfolio in Review

As of Q1 2022, E Fund Management held 374 positions worth $3.06B, up 8% from $2.83B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

E Fund Management deployed $653M of net new capital in Q1 2022, opening 73 new positions and adding to 133 existing holdings. Its largest new stake was Natera: 6,882 shares worth $280K.

By sector, the portfolio is most concentrated in Consumer Discretionary at 63% of assets, up from 61% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was United States Brent Oil Fund, an estimated $6.01M trimmed.

  • E Fund Management's largest Q1 2022 buy was Natera: 6,882 shares worth $280K.
  • E Fund Management added most to Alibaba in Q1 2022, an estimated $334M increase.
  • E Fund Management's biggest Q1 2022 reduction was United States Brent Oil Fund, cutting an estimated $6.01M.
  • E Fund Management fully exited NIO in Q1 2022, selling an estimated $10.7M.
  • E Fund Management's ten largest holdings make up 83% of its $3.06B portfolio in Q1 2022.
  • E Fund Management opened 73 new positions and closed 49 in Q1 2022.
  • E Fund Management's portfolio value rose 8% quarter-over-quarter to $3.06B.

Based on E Fund Management's 13F filing for Q1 2022, filed 12 May 2022.